Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.

Oncologist · 2025 · PMC12622373 · PMID 41124032

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.1300

boldest claim

The sentences

showed a trendP = .10so close (0.05 < p ≤ 0.1)

Patients with FGFR1 alterations showed a trend toward lower PSA 50 rates that did not reach statistical significance (20% vs 51%, OR 0.24, 95% CI 0.05-1.18, P = .10).

also in 53,322 other papers

did not reach statistical significanceP = .13not close (p > 0.1)

Several other alterations showed trends toward lower PSA 50 response rates, though these did not reach statistical significance: CDK12 (25% vs 51%, OR 0.33, 95% CI 0.09-1.25, P = .13), FGFR1 (20% vs 51%, OR 0.24, 95% CI 0.05-1.18, P = .10), KRAS (14% vs 50%, OR 0.17, 95% CI 0.02-1.40, P = .12), and EGFR (25% vs 51%, OR 0.33, 95% CI 0.09-1.25, P = .13).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.